Ciba's Revasc (desirudin) equivalent to heparin for acute MI -- TIMI 9B study.
Executive Summary
CIBA's REVASC EQUIVALENT TO HEPARIN FOR PREVENTION OF DEATH AND MI in patients with acute MI following thrombolysis, according to results from Thrombolysis in Myocardial Infarction (TIMI) 9B trial with the recombinant hirudin product. The results were reported Nov. 12 at a George Washington University Medical Center-sponsored Workshop on Thrombolysis and International Therapy in Acute Myocardial Infarction preceding the annual American Heart Association meeting in Anaheim.